Journal article icon

Journal article

Pursuing Reduction in Fatigue After COVID-19 via Exercise and Rehabilitation (PREFACER): a protocol for a randomised feasibility trial

Abstract:
Introduction: Over 777 million COVID-19 infections have occurred globally, with data suggesting that 10%–20% of those infected develop Long COVID. Fatigue is one of the most common and disabling symptoms of Long COVID. We aim to assess the feasibility and safety of a new, remotely delivered, multimodal rehabilitation intervention, paced to prevent post-exertional malaise (PEM), to support the conduct of a future, definitive randomised trial. Methods and analysis: We will conduct a randomised, two-arm feasibility trial (COVIDEx intervention vs usual care). Sixty participants with Long COVID will be recruited and randomised prior to giving informed consent under a modified Zelen design using 1:1 allocation with random permuted blocks via central randomisation to receive either the COVIDEx intervention or usual care. The 50-minute, remotely delivered, COVIDEx intervention will occur twice weekly for 8 weeks. All participants will wear a non-invasive device throughout their entire study participation, to track heart rate, blood oxygen saturation, steps, sleep and monitor PEM. The primary feasibility objectives will be recruitment rates, intervention fidelity, adherence, acceptability (intervention and design), retention, blinding success and outcome completeness. Secondary objectives will include refined estimates for the standard deviation and correlation between baseline and follow-up measurements of fatigue. Feasibility and clinical outcomes will be collected at baseline, 4, 8, 12 and 24 weeks. Qualitative interviews with participants and physiotherapists will explore intervention acceptability and barriers/facilitators. Ethics and dissemination: Ethical approval for this study was obtained by the Western University Health Sciences Research Ethics Board (REB# 123902). Dissemination plans include sharing of trial findings at conferences and through open access publications and patient/community channels. Trial registration number: NCT06156176
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1136/bmjopen-2025-102112

Authors


More by this author
Role:
Author
ORCID:
0009-0009-8479-3530
More by this author
Role:
Author
ORCID:
0009-0000-0730-0610


More from this funder
Funder identifier:
https://ror.org/02grkyz14
More from this funder
Funder identifier:
https://ror.org/01gavpb45


Publisher:
BMJ Publishing Group
Journal:
BMJ Open More from this journal
Volume:
15
Issue:
11
Article number:
bmjopen-2025-102112
Publication date:
2025-11-09
Acceptance date:
2025-10-07
DOI:
EISSN:
2044-6055
ISSN:
2044-6055


Language:
English
Keywords:
UUID:
uuid_e12bba88-cf68-4753-8b45-93b82d6bd480
Source identifiers:
3457428
Deposit date:
2025-11-10
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP